Compile Data Set for Download or QSAR
Report error Found 799 Enz. Inhib. hit(s) with Target = 'Glutamate receptor ionotropic, NMDA 2A'
TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM50203305(benzyl 4-[(pyridin-4-ylamino)methyl]piperidine-1-c...)
Affinity DataEC50: >1.00E+4nMAssay Description:Activity at human NR2A expressed in Ltk- cells by calcium flux assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521554(US11149054, Compound 1839)
Affinity DataEC50:  295nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521558(US11149054, Compound 1)
Affinity DataEC50:  145nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521559(US11149054, Compound 2)
Affinity DataEC50:  163nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521560(US11149054, Compound 2A)
Affinity DataEC50:  158nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521561(US11149054, Compound 2B)
Affinity DataEC50:  131nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521562(US11149054, Compound 10)
Affinity DataEC50:  125nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521563(US11149054, Compound 1-A)
Affinity DataEC50:  109nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521564(US11149054, Compound 1-B)
Affinity DataEC50:  31.6nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521565(US11149054, Compound 7)
Affinity DataEC50:  300nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521566(US11149054, Compound 9)
Affinity DataEC50:  317nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521567(US11149054, Compound 3)
Affinity DataEC50:  185nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521568(US11149054, Compound 1967)
Affinity DataEC50:  171nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521569(US11149054, Compound 7-B)
Affinity DataEC50:  347nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521570(US11149054, Compound 7-A)
Affinity DataEC50:  248nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521571(US11149054, Compound 8)
Affinity DataEC50:  446nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521572(US11149054, Compound 4)
Affinity DataEC50:  201nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521573(US11149054, Compound 5)
Affinity DataEC50:  182nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521574(US11149054, Compound 6)
Affinity DataEC50:  248nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521575(US11149054, Compound 11)
Affinity DataEC50:  117nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521576(US11149054, Compound 2080)
Affinity DataEC50:  165nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521577(US11149054, Compound 2081)
Affinity DataEC50:  129nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521578(US11149054, Compound 2184)
Affinity DataEC50:  65.8nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521579(US11149054, Compound 2285)
Affinity DataEC50:  764nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521580(US11149054, Compound 2392)
Affinity DataEC50:  104nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521581(US11149054, Compound 2499)
Affinity DataEC50:  768nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521582(US11149054, Compound 2500)
Affinity DataEC50:  63.3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521583(US11149054, Compound 2602)
Affinity DataEC50:  289nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521584(US11149054, Compound 2706)
Affinity DataEC50: >1.00E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521585(US11149054, Compound 2707)
Affinity DataEC50:  119nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521586(US11149054, Compound E-2817)
Affinity DataEC50:  5.07E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521587(US11149054, Compound 2918)
Affinity DataEC50:  298nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521588(US11149054, Compound 3035)
Affinity DataEC50:  61nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521589(US11149054, Compound 3149)
Affinity DataEC50:  69.7nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521590(US11149054, Compound 3266)
Affinity DataEC50:  148nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521591(US11149054, Compound 3382)
Affinity DataEC50:  67.6nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521592(US11149054, Compound 3495)
Affinity DataEC50:  96.7nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521593(US11149054, Compound 3496)
Affinity DataEC50:  35.1nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521594(US11149054, Compound 3507)
Affinity DataEC50:  165nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521595(US11149054, Compound 3634)
Affinity DataEC50:  423nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521596(US11149054, Compound 3788)
Affinity DataEC50:  1.32E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521597(US11149054, Compound 3877)
Affinity DataEC50: >1.00E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521598(US11149054, Compound 3983)
Affinity DataEC50:  88.1nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521599(US11149054, Compound 4023)
Affinity DataEC50:  516nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521600(US11149054, Compound 4155)
Affinity DataEC50:  442nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521601(US11149054, Compound 4156)
Affinity DataEC50: >1.00E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521602(US11149054, Compound 4258)
Affinity DataEC50:  1.03E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521603(US11149054, Compound 4259)
Affinity DataEC50: >1.00E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521604(US11149054, Compound 4360)
Affinity DataEC50: >1.00E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM521605(US11149054, Compound 4475)
Affinity DataEC50:  461nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 799 total ) | Next | Last >>
Jump to: